Actively Recruiting
Pilot Trial of Colchicine for Graft Failure in CABG
Led by Ruijin Hospital · Updated on 2026-01-02
100
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.
CONDITIONS
Official Title
Pilot Trial of Colchicine for Graft Failure in CABG
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Any sex
- Signed informed consent
- Within 3 days after a successful isolated coronary artery bypass grafting (CABG) surgery
You will not qualify if you...
- Allergy to study medication
- Hematopoietic (blood/bone marrow) dysfunction
- Moderate to severe liver dysfunction
- Moderate to severe kidney dysfunction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China
Actively Recruiting
Research Team
Y
Yunpeng Zhu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here